14-day Premium Trial Subscription Sign Up For FreeGet Free

Aurinia Pharmaceuticals Inc Stock Forecast NASDAQ:AUPH

$18.54 (-0.16%)

Volume: 2M

Closed: Jan 19, 2022

Hollow Logo Score: -1.465

Aurinia Pharmaceuticals Inc Stock Forecast

$18.54 (-0.16%)

Volume: 2M

Closed: Jan 19, 2022

Score Hollow Logo -1.465

Aurinia Pharmaceuticals Inc Company Profile

4464 Markham Street

Victoria BC V8Z 7X8



Industry: Biotechnology

Sector: Healthcare

Aurinia Pharmaceuticals Inc


Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company’s lead drug candidate is Voclosporin, a calcineurin inhibitor, which is in Phase IIb clinical trial for the treatment of lupus nephritis. It has a collaboration agreement with Paladin Labs Inc. to maintain the patent portfolio for Voclosporin in Canada, South Africa, and Israel; and development, distribution, and license agreement with 3SBio, Inc. for Voclosporin in China, Hong Kong, and Taiwan. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE